Role of “revascularization surgery” in the management of mandibular osteoradionecrotic lesions: a report of twenty‐one years of experience

Abstract

Experiment based on the conviction of a biological dimension of reconstructive surgery where the contribution of a vascularized transplant within irradiated tissue constitutes a physiological response to hypoxia, hypocellularity and hypovascularization characteristic of osteoradionecrotic injury.

Between 1992 and 2013, 119 osteoradionecrotic lesions were treated requiring 125 free flaps.

Revascularization surgery efficiency rate during the study period of 94%.

Complex surgery: 49% complications including 38% vascular complications (total or partial flap necrosis) and 37% intolerance to osteosynthesis material.

Proposal of a therapeutic algorithm retaining the indication of a revascularization surgery in case of cutaneous osteoradionecrotic damage and/or bone exposure greater than 2 centimeters and/or osteolysis of interest to the lower alveolar canal.

This article is protected by copyright. All rights reserved.

https://ift.tt/2rynSis

hand-foot syndrome due to paclitaxel: A rare case report p. 284 Pritam S Kataria, Pradip P Kendre, Apurva A Patel, Nahush Tahiliani, Vijay Bhargav, Honey Parekh DOI:10.4103/ijp.IJP_547_17 Hand-foot syndrome (HFS) is a relatively frequent adverse reaction to certain anticancer drugs. HFS is a type of dermatitis which has been most commonly described with 5-fluorouracil and capecitabine. However, HFS with paclitaxel is rare and has been reported sparingly in the literature. A 52-year-old male patient with recurrent carcinoma of the buccal mucosa was started on palliative chemotherapy regimen, injection paclitaxel (175 mg/m2) in combination with injection carboplatin. On post-chemotherapy day 13, the patient started developing pain, dysesthesia followed by bullae formation, and desquamation over palms and soles. Clinically, the patient had Grade 3 HFS characterized by symmetrical, tender skin lesions over the dorsal aspect of palms, and soles with desquamation necessitating interrupti

https://plus.google.com/u/0/+AlexandrosGSfakianakis/posts/b1LJWb9JV61

Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study

Conditions:   Parkinson Disease;   Movement Disorders;   Neuro-Degenerative Disease;   Nervous System Diseases;   Brain Diseases
Interventions:   Drug: Cerebral Dopamine Neurotrophic Factor;   Device: Renishaw Drug Delivery System
Sponsors:   Herantis Pharma Plc.;   Renishaw plc.
Recruiting

https://ift.tt/2GfOkYd

A Phase I Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 in Advanced Solid Tumors or Lymphoma

Conditions:   Advanced Cancer;   Gastric Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer Metastatic;   Colo-rectal Cancer;   Solid Tumor;   Solid Carcinoma;   Solid Carcinoma of Stomach;   Cancer of Stomach;   Lymphoma;   Sarcoma;   Cutaneous T Cell Lymphoma;   Head and Neck Squamous Cell Carcinoma
Intervention:   Drug: GZ17-6.02
Sponsors:   Genzada Pharmaceuticals USA, Inc.;   Translational Drug Development
Not yet recruiting

https://ift.tt/2rD6MQG

Oral Cancer With Wide Excision and Free Flap Reconstruction

Condition:   Head and Neck Cancer
Intervention:   Procedure: swallow fuction and swallow training
Sponsor:   National Taiwan University Hospital
Recruiting

https://ift.tt/2GfOr65

The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis

Conditions:   Atopic Dermatitis;   Eczema
Interventions:   Procedure: Water;   Procedure: Bleach;   Procedure: Acetic acid
Sponsors:   Mayo Clinic;   HealthPartners Institute
Not yet recruiting

https://ift.tt/2Lo2aqJ

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Conditions:   Clinical Stage 0 Gastric Cancer AJCC v8;   Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage I Gastric Cancer AJCC v8;   Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIB Gastric Cancer AJCC v8;   Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Gastric Adenocarcinoma;   Localized Gastric Carcinoma;   Localized Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage 0 Gastric Cancer AJCC v8;   Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage I Gastric Cancer AJCC v8;   Pathologic Stage IA Gastric Cancer AJCC v8;   Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IB Gastric Cancer AJCC v8;   Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIA Gastric Cancer AJCC v8;   Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIB Gastric Cancer AJCC v8;   Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions:   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Ipilimumab;   Biological: Nivolumab;   Drug: Oxaliplatin;   Procedure: Therapeutic Conventional Surgery
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting

https://ift.tt/2CdH1fI